loading...| Preferred Name |
aclarubicin |
|
| Synonyms |
MA144-A1 |
|
| Definitions |
An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C202" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C202" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000039131 |
|
| altLabel |
MA144-A1 Aclacinon Aclaplastin ACM-A 1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5, 7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl) -.alpha.-L-lyxo-hexopyranosyl]-3-(dimethylamino)-.alpha.-L-lyxo-hexopyranosyl]oxy]-, methyl ester,(1R-(1.alpha.,2.beta.,4.beta.))-(9CI) Aclacinomycine aclacinomycin Jaclacin Aclacinomycin A Aclacin aclacinomycin-A Aclarubicin Hydrochloride Aclacinomycin A hydrochloride Antibiotic MA144-A1 [1R-(1alpha,2beta,4beta)]-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino-alpha-L-lyxo-hexopyranosyl)oxy]-1-naphthacenecarboxylic acid methyl ester [1R-(1alpha,2beta,4beta)]-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydeo-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino-alpha-L-lyxo-hexopyranosyl)oxy]- ACM |
|
| CAS Registry |
57576-44-0 |
|
| cui |
C1515873 C0771002 C1257665 C1515872 C0001143 C0050561 C0591033 C1515871 C0917820 |
|
| Date last modified |
2007-01-05 |
|
| definition |
An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C202" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C202" NCI Thesaurus) |
|
| IND Code |
16864 |
|
| Legacy PDQ ID |
1752 |
|
| LT |
TRD |
|
| NCI ID |
C202 |
|
| notation |
CDR0000039131 |
|
| NSC Code |
240619 208734 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
aclarubicin |
|
| tui |
T109 T195 T121 |